A novel dual-target inhibitor of QC enzyme and Aβ, its synthesis method and application
By designing a novel dual-target inhibitor of QC enzyme and Aβ, the problems of difficulty in penetrating the blood-brain barrier and high synthesis difficulty of existing QC enzyme inhibitors have been solved, enabling effective treatment of diseases such as Alzheimer's disease. It has excellent blood-brain barrier penetration performance and low cytotoxicity.
Patent Information
- Application Number
- CN202611005252.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-07
- Publication Date
- 2026-11-17
AI Technical Summary
Existing QC enzyme inhibitors are difficult to cross the blood-brain barrier, are difficult to synthesize, cannot effectively intervene in the Aβ aggregation process, and can only reduce the degree of pyroglutamate but cannot eliminate neurotoxicity.
A novel dual-target inhibitor of QC enzyme and Aβ was designed by reacting an aromatic amine with a specific structure, bromoacetyl chloride, and a 1-(3-aminopropyl)imidazole derivative in the presence of an acid-binding agent to generate an inhibitor with blood-brain barrier penetration properties.
It achieves QC enzyme inhibition activity, Aβ aggregation inhibition activity, and Aβ aggregate disaggregation promotion activity, with good blood-brain barrier permeability and low cytotoxicity, making it suitable for drugs to treat diseases such as Alzheimer's disease, while reducing the difficulty and cost of synthesis.
Smart Images

Figure CN123106544A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a novel dual-target inhibitor of QC enzyme and Aβ, its synthesis method, and its application. Background Technology
[0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss, cognitive decline, and language and behavioral impairments. Its current prevalence is severe, posing a serious threat to human health. Beta-amyloid (Aβ) is a core component of senile plaques, one of the three major pathological features of AD. Due to its strong aggregation activity and neurotoxicity, Aβ is widely considered a key factor in inducing AD. Research has found that glutamine acylcyclase (QC) can mediate the post-translational modification of Aβ, generating pyroglutamylated Aβ (pE-Aβ), which has stronger aggregation ability and neurotoxicity, thus accelerating the development and deterioration of AD. QC has become a potential new target for anti-AD drug development, with the representative QC inhibitor PQ912 having entered Phase IIb clinical trials.
[0003] Classic QC enzyme inhibitors primarily mimic the structural features of Aβ3-5 (Glu-Phe-Arg) to construct substrate analogs that competitively inhibit the catalytic center of QC enzymes. Their pharmacophores are characterized by the following: possessing Zn atoms that can bind to the active site. 2+ The complexed imidazole or benzimidazole group is the core pharmacophore for inhibitory activity. Opposite it is the aromatic structural region, which occupies the Phe site of the substrate and forms π-π stacking interactions with the enzyme's Phe325 residue. The middle region contains urea or thiourea structures, which act as hydrogen bond donors or acceptors when binding to QC. These characteristics ensure high inhibitory activity of QC enzymes. However, the presence of highly polar groups such as urea and thiourea in the structural framework makes it difficult for compounds to cross the blood-brain barrier and reduce efficacy, while also increasing the difficulty of compound synthesis, involving the use of high-risk phosgene or thiophosgene. Furthermore, QC enzyme inhibitors can theoretically only reduce the degree of Aβ pyroglutamate transformation, and cannot interfere with the existing full-length Aβ aggregation process to eliminate its neurotoxicity. Summary of the Invention
[0004] To address the problems existing in the prior art, this invention provides a novel dual-target inhibitor of QC enzyme and Aβ, its synthesis method, and its application. This inhibitor has a simple molecular structure, is easy to synthesize, and has excellent blood-brain barrier penetration performance.
[0005] The technical solution adopted to achieve the above-mentioned objective of this invention is: a novel dual-target inhibitor of QC enzyme and Aβ, the general structural formula of which is as follows:
[0006] or ; R1, R2, and R3 are each independently selected from hydrogen and methyl; R4, R5, R6, R7, and R8 are respectively hydrogen, chlorine, bromine, methyl, methoxyformyl, methoxyacetyl, ethynyl, 2-propynyloxy, phenyl, tert-butyl, and 4-chlorophenyl. Or any two adjacent groups among R4, R5, R6, R7, and R8, together with the carbon atom of the benzene ring to which they are attached, fused together to form a 4-methyl-2-oxo-2H-pyran ring; R9 is selected from bromine.
[0007] Furthermore, the inhibitor is selected from compounds with the following structural formula:
[0008] Furthermore, the inhibitor is selected from compounds with the following structural formula: .
[0009] A novel method for synthesizing a QC enzyme and an Aβ dual-target inhibitor includes the following steps: S1. In the presence of an acid-binding agent, aromatic amines and bromoacetyl chloride undergo a substitution reaction to generate a bromoacetyl-aromatic amine intermediate; S2. In the presence of an acid-binding agent, the bromoacetyl-aromatic amine intermediate undergoes a substitution reaction with 1-(3-aminopropyl)imidazole or a 1-(3-aminopropyl)imidazole derivative to generate the novel QC enzyme and Aβ dual-target inhibitor.
[0010] Furthermore, the acid-binding agent is selected from at least one of potassium carbonate, sodium carbonate, cesium carbonate, triethylamine, and N,N-diisopropylethylamine.
[0011] Furthermore, in steps S1 and S2, the reaction solvent used is selected from at least one of acetone, dichloromethane, chloroform, acetonitrile, tetrahydrofuran, and dioxane.
[0012] Furthermore, in S1, the substitution reaction temperature is -5 to 15 °C, the reaction time is 0.5 to 2 h, and the molar ratio of aromatic amine, bromoacetyl chloride, and acid-binding agent is 1:1 to 4:1 to 8; in S2, the substitution reaction temperature is 30 to 80 °C, the reaction time is 1 to 4 h, and the molar ratio of bromoacetyl-aromatic amine intermediate, 1-(3-aminopropyl)imidazole or 1-(3-aminopropyl)imidazole derivative, and acid-binding agent is 1:1 to 2:1 to 10.
[0013] Application of a novel QC enzyme and Aβ dual-target inhibitor in the preparation of drugs for treating diseases caused by Aβ aggregation.
[0014] Furthermore, the diseases mentioned include Alzheimer's disease, cerebrovascular dementia, or glaucoma.
[0015] Compared with the prior art, the advantages and beneficial effects of the present invention are as follows: 1. The inhibitor of the present invention not only has QC enzyme inhibitory activity, Aβ aggregation inhibitory activity and Aβ aggregate disaggregation activity, but also has relatively ideal blood-brain barrier permeability and low cytotoxicity. It is suitable for the synthesis of drugs to treat diseases caused by Aβ aggregation, such as Alzheimer's disease, cerebrovascular dementia or glaucoma, and has strong clinical development prospects.
[0016] 2. Compared with classic thiourea QC enzyme inhibitors, the inhibitor of the present invention has a simpler molecular structure, is free of urea and thiourea structural features, and has significantly reduced synthesis difficulty and cost, while greatly improving synthesis efficiency. Attached Figure Description
[0017] Figure 1 This is a graph showing the inhibitory effect of the dual-target inhibitors Q1-Q18 on QC enzyme activity.
[0018] Figure 2 The graph shows the inhibitory effects of various representative dual-target inhibitors on QC enzyme activity at different concentrations.
[0019] Figure 3 This is a graph showing the inhibitory effect of the dual-target inhibitor Q1-Q18 on Aβ42 protein aggregation.
[0020] Figure 4 The graph shows the inhibitory effect of different concentrations of the dual-target inhibitor Q7 on Aβ42 protein aggregation.
[0021] Figure 5 This is a diagram illustrating the effect of the dual-target inhibitor Q1-Q18 on the disaggregation of Aβ aggregates.
[0022] Figure 6 The graph shows the effect of different concentrations of the dual-target inhibitor Q7 on the disaggregation of Aβ aggregates.
[0023] Figure 7 The figure shows the cytotoxicity results of various representative dual-target inhibitors at different concentrations on human neuroblastoma cells SH-SY5Y.
[0024] Figure 8 This is a schematic diagram of the docking pattern between the dual-target inhibitor Q7 and the QC enzyme molecule. Detailed Implementation
[0025] To facilitate understanding and implementation of the present invention by those skilled in the art, the present invention will be further described in detail below with reference to embodiments. It should be understood that the embodiments described herein are for illustration and explanation only and are not intended to limit the present invention.
[0026] Example 1: Synthesis of Inhibitor Q1 1. Dissolve o-bromoaniline (172 mg, 1.0 mmol) in 15 mL of dichloromethane in a 100 mL two-necked flask. Add triethylamine (303.6 mg, 3.0 mmol). After cooling with stirring in an ice bath (0°C), mix 15 mL of dichloromethane and bromoacetyl chloride (236.0 mg, 1.5 mmol) thoroughly in a dropping funnel, and then slowly add it dropwise to the two-necked flask. Monitor the reaction progress using thin-layer chromatography (TLC) (mobile phase is a mixture of petroleum ether and ethyl acetate). After the reaction is complete, quench excess bromoacetyl chloride with methanol. After stirring for 10 minutes, add silica gel and rotary evaporate the solvent under reduced pressure to obtain a silica gel sample. Filter the sample onto a silica gel column for purification. Use a mixture of petroleum ether and ethyl acetate (petroleum ether:ethyl acetate = 20:1, volume ratio) as the mobile phase. Collect the eluent of the target product and remove the mobile phase by rotary evaporation under reduced pressure to obtain the intermediate product 2-bromo-N-(2-bromophenyl)acetamide, a white solid with a yield of up to 95%.
[0027] 2. 2-Bromo-N-(2-Bromophenyl)acetamide (1.0 mmol, 293.0 mg) and 1-(3-aminopropyl)imidazole (1.0 mmol, 125.2 mg) were added to acetonitrile and stirred to dissolve. Then, potassium carbonate (2.0 mmol, 276.4 mg) was added as an acid-binding agent. The mixture was then heated to 60°C with stirring and stirred for 2 h. The reaction progress was monitored by TLC. After the reaction was completed, potassium carbonate was removed by filtration. Silica gel was added and the solvent was removed by rotary evaporation under reduced pressure to obtain a silica gel sample. The sample was then purified by silica gel column chromatography using a mixture of dichloromethane and methanol (dichloromethane:methanol = 20:1, volume ratio). The eluent was collected and the mobile phase was removed by rotary evaporation under reduced pressure to obtain the dual-target inhibitor Q1, a yellow oily substance with a yield of 72%.
[0028] 1HNMR (600 MHz, Chloroform-d) δ 9.87 (s, 1H), 8.47 (dd, J = 8.2, 1.5Hz, 1H), 7.55 (dd, J = 8.0, 1.4 Hz, 1H), 7.49 (s, 1H), 7.35 - 7.31 (m, 1H),7.07 (s, 1H), 6.99 (td, J = 7.7, 1.6 Hz, 1H), 6.93 (s, 1H), 4.10 (t, J = 7.0Hz, 2H), 3.43 (s, 2H), 2.73 (t, J = 6.9 Hz, 2H), 2.04 (p, J = 6.9 Hz, 2H).
[0029] Example 2: Synthesis of Inhibitor Q2 The synthesis method of Q2 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with m-bromoaniline.
[0030] 1 HNMR (600 MHz, Chloroform-d) δ 9.07 (s, 1H), 7.82 (t, J = 2.0 Hz,1H), 7.53 (s, 1H), 7.51 - 7.47 (m, 1H), 7.24 (dt, J = 8.0, 1.3 Hz, 1H), 7.19(t, J = 8.0 Hz, 1H), 7.08 (t, J = 1.2 Hz, 1H), 6.92 (t, J = 1.3 Hz, 1H), 4.06(t, J = 6.9 Hz, 2H), 3.38 (s, 2H), 2.71 (t, J = 7.0 Hz, 2H), 2.02 (p, J = 7.0Hz, 2H).
[0031] 13 CNMR (151 MHz, CDCl3) δ 169.41, 138.79, 137.09, 130.39, 129.73,127.32, 122.72, 122.40, 118.75, 117.96, 53.05, 47.26, 44.88, 31.41.
[0032] HRMS (ESI): calcd for C 14 H 17 BrN4O [M+H] +337.0659, found [M+H] + 337.0859.
[0033] Example 3: Synthesis of Inhibitor Q3 The synthesis method of Q3 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with methyl 4-amino-3-bromobenzoate (CAS No.: 106896-49-5).
[0034] 1 HNMR (600 MHz, DMSO-d6) δ 8.86 (d, J = 2.1 Hz, 1H), 7.83 (d, J = 8.3Hz, 1H), 7.63 - 7.59 (m, 2H), 7.16 (t, J = 1.3 Hz, 1H), 6.87 (t, J = 1.1 Hz,1H), 4.06 (t, J = 7.0 Hz, 2H), 3.87 (s, 3H), 3.31 (s, 2H), 2.54 (t, J = 7.0Hz, 2H), 1.92 (p, J = 7.0 Hz, 2H).
[0035] 13 CNMR (151 MHz, DMSO) δ 171.24, 165.97, 137.69, 136.59, 133.53,130.17, 128.86, 125.97, 121.85, 119.75, 119.08, 53.14, 52.93, 46.86, 44.37,31.54.
[0036] HRMS (ESI): calcd for C 16 H 19 BrN4O3[M+H] + 395.0713, found[M+H] + 395.0971.
[0037] Example 4: Synthesis of Inhibitor Q4 The synthesis method of Q4 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with methyl 3-amino-5-bromobenzoate (CAS No.: 706791-83-5).
[0038] 1HNMR (600 MHz, DMSO-d6) δ 8.25 (t, J = 1.7 Hz, 1H), 8.21 (t, J = 2.0Hz, 1H), 7.73 (t, J = 1.7 Hz, 1H), 7.61 (d, J = 1.2 Hz, 1H), 7.17 - 7.14 (m,1H), 6.87 (t, J = 1.1 Hz, 1H), 4.04 (t, J = 7.0 Hz, 2H), 3.87 (s, 3H), 3.32(s, 2H), 2.50 - 2.48 (m, 2H), 1.86 (p, J = 6.9 Hz, 2H).
[0039] 13 CNMR (151 MHz, DMSO) δ 171.55, 165.29, 141.08, 137.71, 132.46,128.76, 126.43, 126.16, 122.14, 119.77, 119.18, 53.15, 53.06, 46.21, 44.30,31.23.
[0040] HRMS (ESI): calcd for C 16 H 19 BrN4O3[M+H] + 395.0713, found[M+H] + 395.0971.
[0041] Example 5: Synthesis of Inhibitor Q5 The synthesis method of Q5 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with methyl 3-aminophenylacetate (CAS No.: 52913-11-8).
[0042] 1HNMR (600 MHz, DMSO-d6) δ 7.60 (t, J = 1.0 Hz, 1H), 7.53 (dd, J =7.3, 1.3 Hz, 2H), 7.25 (td, J = 7.5, 1.4 Hz, 1H), 7.15 (t, J = 1.2 Hz, 1H), 6.95 (dt, J = 7.3, 1.4 Hz, 1H), 6.87 (t, J = 1.1 Hz, 1H), 4.04 (t, J = 7.1Hz, 2H), 3.64 (s, 2H), 3.61 (s, 3H), 3.26 (s, 2H), 2.48 (t, J = 6.7 Hz, 2H),1.85 (p, J = 6.9 Hz, 2H).
[0043] 13 CNMR (151 MHz, DMSO) δ 171.98, 170.81, 139.23, 137.72, 135.35,129.21, 128.78, 124.77, 120.43, 119.77, 118.22, 53.20, 52.19, 46.31, 44.34,40.76, 31.39.
[0044] HRMS (ESI): calcd for C 17 H 22 N4O3[M+H] + 331.1765, found[M+H] + 331.2004.
[0045] Example 6: Synthesis of Inhibitor Q6 The synthesis method of Q6 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with m-aminophenylacetylene (CAS No.: 54060-30-9).
[0046] 1HNMR (600 MHz, DMSO-d6) δ 9.87 (s, 1H), 7.82 (t, J = 1.9 Hz, 1H), 7.64 - 7.62 (m, 1H), 7.60 (s, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.16 (td, J =3.7, 3.0, 1.5 Hz, 2H), 7.01 (s, 1H), 6.87 (s, 1H), 4.15 (s, 1H), 4.04 (t, J =7.0 Hz, 2H), 3.28 (s, 2H), 2.48 (t, J = 6.7 Hz, 2H), 1.86 (p, J = 6.9 Hz, 2H).
[0047] 13 CNMR (151 MHz, DMSO) δ 171.11, 139.38, 137.72, 135.61, 129.65,128.77, 126.99, 122.47, 120.32, 119.76, 83.85, 81.03, 53.21, 46.30, 44.34,31.34.
[0048] HRMS (ESI): calcd for C 16 H 18 N4O [M+H] + 283.1533, found[M+H] + 283.1637.
[0049] Example 7: Synthesis of Inhibitor Q7 The synthesis method of Q7 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with p-aminophenylacetylene (CAS No.: 14235-81-5).
[0050] 1 H NMR (600 MHz, DMSO-d6) δ 7.69 - 7.65 (m, 2H), 7.61 (s, 1H), 7.43 -7.40 (m, 2H), 7.16 (s, 1H), 6.86 (s, 1H), 4.04 (t, J = 7.0 Hz, 2H), 3.28 (s,2H), 2.46 (t, J = 6.7 Hz, 2H), 1.85 (p, J = 6.9 Hz, 2H). 13C NMR (151 MHz, DMSO) δ 171.21, 139.79, 137.74, 132.82, 128.76,119.79, 119.50, 116.59, 84.04, 80.31, 53.27, 46.24, 44.33, 31.37.
[0051] HRMS (ESI): calcd for C 16 H 18 N4O [M+H] + 283.1533, found[M+H] + 283.1614.
[0052] Example 8: Synthesis of Inhibitor Q8 The synthesis method of Q8 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 4-(2-propynyloxy)aniline (CAS No.: 26557-78-8).
[0053] 1 HNMR (600 MHz, DMSO-d6) δ 9.65 (s, 1H), 7.60 (s, 1H), 7.55 - 7.52(m, 2H), 7.15 (s, 1H), 6.95 - 6.92 (m, 2H), 6.87 (s, 1H), 4.74 (d, J 1.85 (p, J = 6.8 Hz, 2H).
[0054] 13 CNMR (151 MHz, DMSO) δ 170.31, 153.60, 137.72, 133.03, 128.78,121.13, 119.76, 115.46, 79.86, 78.54, 56.09, 53.14, 46.35, 44.35, 31.37.
[0055] HRMS (ESI): calcd for C 17 H 20 N4O2[M+H] +313.1659, found [M+H] + 313.1776.
[0056] Example 9: Synthesis of Inhibitor Q9 The synthesis method of Q9 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 3-amino-6-bromobiphenyl (CAS No.: 1036750-83-0).
[0057] 1 HNMR (600 MHz, DMSO-d6) δ 7.71 (d, J = 2.6 Hz, 1H), 7.65 (d, J = 8.7Hz, 1H), 7.62 - 7.59 (m, 2H), 7.48 - 7.45 (m, 2H), 7.43 - 7.41 (m, 1H), 7.39- 7.37 (m, 2H), 7.15 (t, J = 1.3 Hz, 1H), 6.86 (d, J = 1.1 Hz, 1H), 4.03 (t,J = 7.0 Hz, 2H), 3.31 (s, 2H), 2.49 - 2.48 (m, 2H), 1.86 (p, J = 6.9 Hz, 2H).
[0058] 13 CNMR (151 MHz, DMSO) δ 170.91, 142.53, 140.93, 138.85, 137.71,133.64, 129.48, 128.77, 128.64, 128.26, 122.25, 120.40, 119.76, 115.32,53.07, 46.22, 44.29, 31.16.
[0059] HRMS (ESI): calcd for C 20 H 21 BrN4O [M+H] + 413.0972, found[M+H] + 413.1270.
[0060] Example 10: Synthesis of Inhibitor Q10 The synthesis method of Q10 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with N-methylbiphenyl-2-amine (CAS No.: 14925-09-8).
[0061] 1 HNMR (600 MHz, DMSO-d6) δ 7.52 (d, J = 1.2 Hz, 1H), 7.49 (ddd, J =6.7, 3.7, 2.1 Hz, 2H), 7.47 - 7.44 (m, 2H), 7.42 (dd, J = 7.2, 1.1 Hz, 2H),7.39 - 7.38 (m, 1H), 7.33 (d, J = 1.6 Hz, 1H), 7.32 (t, J = 1.3 Hz, 1H), 7.07(t, J = 1.3 Hz, 1H), 6.85 (d, J = 1.1 Hz, 1H), 3.90 (t, J = 7.0 Hz, 2H), 3.00(d, J = 16.1 Hz, 1H), 2.96 (s, 3H), 2.71 (d, J = 16.2 Hz, 1H), 2.22 - 2.17(m, 1H), 2.14 (dt, J = 11.6, 6.8 Hz, 1H), 1.64 (p, J = 6.9 Hz, 2H).
[0062] 13 CNMR (151 MHz, DMSO) δ 170.71, 140.46, 139.61, 138.86, 137.66,131.64, 129.64, 129.21, 129.08, 128.78, 128.72, 128.15, 119.72, 50.94, 45.94, 44.24, 37.34, 31.26.
[0063] HRMS (ESI): calcd for C 21 H 24 N4O[M+H] + 349.2023, found[M+H] + 349.2294.
[0064] Example 11: Synthesis of Inhibitor Q11 The synthesis method of Q11 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 5-chlorobiphenyl-2-amine (CAS No.: 73006-78-7).
[0065] 1HNMR (600 MHz, DMSO-d6) δ 8.31 (d, J = 8.8 Hz, 1H), 7.51 (s, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.44 (dd, J = 8.9, 2.6 Hz, 1H), 7.42 (d, J = 1.7Hz, 1H), 7.42 - 7.38 (m, 2H), 7.29 (d, J = 2.6 Hz, 1H), 7.06 (s, 1H), 6.88(s, 1H), 3.76 (t, J = 7.1 Hz, 2H), 3.12 (s, 2H), 2.26 (t, J = 6.9 Hz, 2H),1.54 (p, J = 6.9 Hz, 2H).
[0066] 13 CNMR (151 MHz, DMSO) δ 170.58, 137.59, 137.01, 134.49, 134.38,130.05, 129.49, 128.80, 128.67, 128.40, 128.06, 122.57, 119.67, 52.94, 46.57, 44.10, 31.11.
[0067] HRMS (ESI): calcd for C 20 H 21 ClN4O[M+H] + 369.1477, found[M+H] + 369.1748.
[0068] Example 12: Synthesis of Inhibitor Q12 The synthesis method of Q12 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 5-(1,1-dimethylethyl)-(1,1'-biphenyl)-2-amine (CAS No.: 1410783-24-2).
[0069] HRMS (ESI): calcd for C 25 H 32 ClN4O[M+H] + 405.2649, found[M+H] + 405.2654.
[0070] Example 13: Synthesis of Inhibitor Q13 The synthesis method of Q13 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 8-bromo-1-naphthylamine (CAS No.: 62456-34-2).
[0071] 1 HNMR (600 MHz, DMSO-d6) δ 8.01 (dd, J = 8.2, 1.2 Hz, 1H), 7.92 (dd,J = 8.0, 1.6 Hz, 1H), 7.86 (dd, J = 7.4, 1.2 Hz, 1H), 7.63 - 7.56 (m, 3H), 7.38 (t, J = 7.8 Hz, 1H), 7.16 (d, J = 1.3 Hz, 1H), 6.87 (d, J = 1.2 Hz, 1H), 4.07 (t, J = 7.0 Hz, 2H), 3.36 (s, 2H), 2.57 (t, J = 6.8 Hz, 2H), 1.89 (p, J= 6.8 Hz, 2H).
[0072] 13 CNMR (151 MHz, DMSO) δ 171.21, 137.74, 136.69, 134.13, 133.28,129.76, 128.79, 128.14, 127.67, 126.88, 126.85, 126.75, 119.77, 116.73,53.28, 46.70, 44.36, 31.42.
[0073] HRMS (ESI): calcd for C 18 H 19 BrN4O[M+H] + 387.0815, found[M+H] + 387.1083.
[0074] Example 14: Synthesis of Inhibitor Q14 The synthesis method of Q14 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 1-amino-2-bromonaphthalene (CAS No.: 771-14-2).
[0075] 1HNMR (600 MHz, Chloroform-d) δ 9.04 (s, 1H), 7.83 (dd, J = 6.8, 2.5Hz, 1H), 7.80 - 7.76 (m, 1H), 7.66 (q, J = 8.8 Hz, 2H), 7.55 - 7.50 (m, 2H),7.50 (s, 1H), 7.06 (s, 1H), 6.93 (s, 1H), 4.09 (t, J = 6.9 Hz, 2H), 3.56 (s,2H), 2.87 - 2.84 (m, 2H), 2.07 (p, J = 7.0 Hz, 2H).
[0076] 13 CNMR (151 MHz, CDCl3) δ 170.49, 137.08, 133.18, 131.53, 131.15,129.78, 129.38, 128.96, 128.28, 127.32, 126.63, 123.73, 119.61, 118.77,52.87, 47.46, 44.84, 31.59.
[0077] HRMS (ESI): calcd for C 18 H 19 BrN4O[M+H] + 387.0815, found[M+H] + 387.1083.
[0078] Example 15: Synthesis of Inhibitor Q15 The synthesis method of Q15 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 7-amino-4-methylcoumarin (CAS:26093-31-2).
[0079] 1HNMR (600 MHz, DMSO-d6) δ 7.82 (d, J = 2.0 Hz, 1H), 7.72 (d, J = 8.6Hz, 1H), 7.61 (s, 1H), 7.56 (dd, J = 8.6, 2.1 Hz, 1H), 7.16 (d, J = 1.3 Hz,1H), 6.87 (s, 1H), 6.26 (d, J = 1.5 Hz, 1H), 4.05 (t, J = 7.0 Hz, 2H), 3.35(s, 2H), 2.50 - 2.48 (m, 2H), 2.40 (d, J = 1.2 Hz, 3H), 1.87 (p, J = 6.8 Hz, 2H).
[0080] 13 CNMR (151 MHz, DMSO) δ 171.64, 160.50, 154.13, 153.59, 142.52,137.73, 128.78, 126.40, 119.78, 115.74, 115.51, 112.73, 106.13, 53.27, 46.26, 44.32, 31.30, 18.46.
[0081] HRMS (ESI): calcd for C 18 H 20 N4O3[M+H] + 341.1608, found[M+H] + 341.1878.
[0082] Example 16: Synthesis of the inhibitor Q16 The synthesis method of Q16 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 4'-chloro-2-aminobiphenyl (CAS No.: 1204-44-0).
[0083] 1HNMR (600 MHz, Chloroform-d) δ 9.19 (s, 1H), 8.34 (d, J = 8.6 Hz,1H), 7.44 - 7.33 (m, 7H), 7.23 (d, J = 2.4 Hz, 1H), 7.05 (s, 1H), 6.76 (s,1H), 3.62 (t, J = 7.2 Hz, 2H), 3.27 (s, 2H), 2.42 (t, J = 6.8 Hz, 2H), 1.59(p, J = 6.9 Hz, 2H), 1.33 (s, 9H).
[0084] 13 CNMR (151 MHz, CDCl3) δ 169.23, 147.12, 139.15, 136.92, 132.01,131.67, 129.54, 129.25, 128.85, 127.69, 127.13, 125.48, 120.36, 118.70,53.20, 46.86, 44.45, 34.44, 31.38, 31.14.
[0085] HRMS (ESI): calcd for C 24 H 30 N4O[M+H] + 391.2492, found [M+H] + 391.2734.
[0086] Example 17: Synthesis of the inhibitor Q17 The synthesis method of Q17 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 5-(1,1-dimethylethyl)-(1,1'-biphenyl)-2-amine (CAS No.: 1410783-24-2), and 1-(3-aminopropyl)imidazole is replaced with 5-methyl-1H-imidazole-1-propylamine (CAS: 279236-77-0).
[0087] 1HNMR (600 MHz, Chloroform-d) δ 9.19 (s, 1H), 8.34 (d, J = 8.6 Hz,1H), 7.44 - 7.33 (m, 7H), 7.23 (d, J = 2.4 Hz, 1H), 7.05 (s, 1H), 6.76 (s,1H), 3.62 (t, J = 7.2 Hz, 2H), 3.27 (s, 2H), 2.42 (t, J = 6.8 Hz, 2H), 1.59(p, J = 6.9 Hz, 2H), 1.33 (s, 9H).
[0088] 13 CNMR (151 MHz, CDCl3) δ 169.23, 147.12, 139.15, 136.92, 132.01,131.67, 129.54, 129.25, 128.85, 127.69, 127.13, 125.48, 120.36, 118.70,53.20, 46.86, 44.45, 34.44, 31.38, 31.14.
[0089] HRMS (ESI): calcd for C 24 H 30 N4O[M+H] + 391.2492, found [M+H] + 391.2734.
[0090] Example 18: Synthesis of Inhibitor Q18 The synthesis method of Q18 is basically the same as that of Q1 in Example 1, except that o-bromoaniline is replaced with 3-amino-4-methylbiphenyl (CAS No.: 80938-67-6). 1HNMR (600 MHz, Chloroform-d) δ 9.11 (s, 1H), 8.34 (s, 1H), 7.65 -7.58 (m, 2H), 7.50 (s, 1H), 7.41 (t, J = 7.8 Hz, 2H), 7.34 - 7.29 (m, 2H),7.25 (d, J = 8.0 Hz, 1H), 7.08 (s, 1H), 6.92 (s, 1H), 4.06 (t, J = 7.0 Hz,2H), 3.44 (s, 2H), 2.75 (t, J = 7.1 Hz, 2H), 2.30 (s, 3H), 2.04 (p, J = 7.1Hz, 2H).
[0091] 13 CNMR (151 MHz, CDCl3) δ 169.15, 140.70, 140.12, 137.05, 135.97,130.81, 129.85, 128.70, 127.25, 127.13, 126.56, 123.32, 120.22, 118.70,53.27, 47.31, 44.82, 31.66, 17.44.
[0092] HRMS (ESI): calcd for C21H24N4O[M+H] + 349.2023, found[M+H] + 349.2294.
[0093] Experiment 1: QC enzyme inhibitory activity test of the novel QC enzyme and Aβ dual-target inhibitor of the present invention. Assay Methods (QC enzyme inhibitory activity of dual-target inhibitors was assessed using the SensoLyte Green QC Enzyme Activity Assay Kit): 1. Dilute the dual-target inhibitor Q1 synthesized in Example 1 to 100 µM using the kit sample dilution buffer (i.e., detection buffer); 2. Add Q1 solution and QC enzyme solution to a 96-well black microplate and incubate at 37°C in the dark to allow the inhibitor Q1 to fully bind with the QC enzyme; 3. Add QC green substrate to each well, gently shake to mix, and continue to incubate at 37°C in the dark for 1 hour. At this time, the final concentration of inhibitor Q1 is 10 µM. 4. After incubation, add glutamine cyclase chromogenic agent to each well and continue incubation at 37°C. This chromogenic agent will specifically cleave and remove pGlu residues, exposing the green fluorescent group.
[0094] 5. Use a fluorescence microplate reader to detect and record the fluorescence intensity of each well.
[0095] 6. The dual-target inhibitors Q2-Q18, PBD-150, and benzylimidazole were tested according to steps 1-5.
[0096] 7. Set up a QC enzyme control experiment without dual-target inhibitors and a blank control experiment. The blank control experiment is used to subtract background fluorescence interference.
[0097] 8. Calculate the inhibition rate of each dual-target inhibitor on QC enzyme activity using the following formula: Inhibition rate = (1-IF) i / IF c )×100%; Among them, IF i The IF value is calculated by subtracting the solvent background fluorescence value from the fluorescence value of the test sample group containing the dual-target inhibitor. c The fluorescence value of the QC enzyme control group without dual-target inhibitors is the result of subtracting the solvent background fluorescence value.
[0098] Experimental results: The inhibitory effects of dual-target inhibitors Q1-Q18, PBD-150, and benzylimidazole on QC enzyme activity are as follows: Figure 1 As shown, by Figure 1 It was found that the dual-target inhibitors Q5, Q7, Q8, Q9, Q10, and Q15 showed good inhibitory effects on QC enzyme activity, reaching over 75%. Among them, the dual-target inhibitor Q7 exhibited the best activity, achieving 100% inhibition, comparable to the positive PBD-150. The benzylimidazole control inhibitor included in the kit, with a test concentration of 100 µM, 10 times the detection concentration of the dual-target inhibitor of this invention, showed an inhibitory activity of approximately 90%, which is essentially consistent with the results stated in the kit's instructions, confirming the accuracy of this test.
[0099] Experiment 2: The IC50 of the novel QC enzyme and Aβ dual-target inhibitor of this invention on QC enzyme activity. 50 Tests and trials Test method: 1. Using the sample diluent from the kit as the diluent, prepare gradient working solutions of the dual-target inhibitor Q7 with concentrations of 12.5, 25, 50, 100, and 200 µM. 2. Conduct the tests with gradient working solutions of various concentrations according to steps 2-5 of Experiment 1. The final concentrations for Q7 inhibition were 1.25, 2.5, 5, 10, and 20 µM, respectively.
[0100] 3. Set up a QC enzyme control experiment without dual-target inhibitors and a blank control experiment. The blank control experiment is used to subtract background fluorescence interference.
[0101] 4. Calculate the inhibition rates of QC enzyme activity by gradient working solutions of different Q7 concentrations. Plot the logarithm of the gradient working solution concentrations on the x-axis and the inhibition rate of the corresponding gradient working solution on the y-axis. Use software such as GraphPad Prism to perform nonlinear regression fitting, plot the dose-response curves, and calculate the IC50 of each compound. 50 value.
[0102] 5. Test the dual-target inhibitors Q5, Q8, Q9, Q10, and Q15 according to the methods in steps 1-4.
[0103] Experimental results: The inhibition rates of various dual-target inhibitors on QC enzyme activity at different concentrations are as follows: Figure 2 As shown, according to Figure 2 The results were used to calculate the half-maximal inhibitory concentration (IC50) of each dual-target inhibitor. 50 .
[0104] The IC50 values of dual-target inhibitors Q5, Q7, Q8, Q9, Q10, and Q15 on QC enzyme activity are shown in Table 1 below: Table 1. IC50 values / µM of representative dual-target inhibitors for QC enzyme activity inhibition.
[0105] Table 1 shows that the IC50 of the dual-target inhibitors Q5, Q7, Q8, Q9, Q10, and Q15 on QC enzyme activity 50 All were around 5.0 µM, with Q7 being the strongest at 5.065 µM, generally slightly weaker than the positive PBD-150 (IC50 value). 50 = 1.717 µM), which still has significant advantages considering its highly simplified molecular structure.
[0106] Experiment 3: Anti-Aβ activity test of the novel QC enzyme and Aβ dual-target inhibitor of the present invention. Test method: 1. Take 1 mg of Aβ 1-42 (hereinafter referred to as Aβ) was added to hexafluoroisopropanol and sonicated to promote dissolution, then freeze-dried, redissolved in DMSO (dimethyl sulfoxide), and diluted with cold PBS solution to obtain Aβ monomer solution.
[0107] 2. Take 10 μL of 40 μM Aβ monomer solution and 10 μL of 400 μM Q1 solution into a 200 μL EP tube, mix well, and then incubate at 37°C for 72 hours (i.e., Q1 is 10 times the equivalent of Aβ). After incubation, add 180 μL of 5 μM thioflavin T (ThT) solution to the EP tube, mix well, and react at room temperature in the dark for 5 min. Use a multichannel pipette to add 180 μL of the reaction mixture to black 96-well plates, and then place them in an Infinite M1000 multi-mode microplate reader (excitation wavelength 444 nm, absorption wavelength 484 nm) to measure and record the fluorescence intensity of each well.
[0108] 3. Take 10 μL of 40 μM Aβ monomer solution as a negative control and 10 μL of PBS solution as a blank control.
[0109] 4. Calculate the inhibition rate of Aβ42 protein self-aggregation by the dual-target inhibitor Q1 using the following formula: Inhibition rate = (1-IF) i / IF c )×100%, Among them, IF i The IF value is calculated by subtracting the background fluorescence value from the fluorescence value of the test sample containing the dual-target inhibitor Q1. c The fluorescence absorbance of the negative control sample is minus the background fluorescence value.
[0110] 5. The dual-target inhibitors Q2-Q18 and PBD-150 were tested according to the methods in steps 1-4.
[0111] 6. Prepare Q7 solutions with concentrations of 40, 200, 400, 1000, and 2000 μM for the dual-target inhibitor Q7. Test each concentration of Q7 solution according to the methods in steps 1-4. That is, the final concentration equivalent ratio of the inhibitor to Aβ is 1, 5, 10, 25, and 50.
[0112] Experimental results: The inhibitory effects of dual-target inhibitors Q1-Q18 and PBD-150 on Aβ42 protein aggregation are as follows: Figure 3 As shown, by Figure 3 It can be seen that the dual-target inhibitor Q7 affects Aβ 42 Protein aggregation exhibited the strongest inhibitory activity, and the dual-target inhibitors Q6, Q8, Q10 and Q13 also showed significant inhibitory activity, which was significantly stronger than the positive QC enzyme inhibitor PBD-150.
[0113] The effect of Q7 solutions of different concentrations on Aβ 42 The inhibitory effect on protein aggregation is shown in [reference needed]. Figure 4 , Figure 4 The results showed that Q7 inhibited Aβ aggregation in a concentration-dependent manner, and even at a 1 eq. equivalent ratio, it produced a significant inhibitory activity of more than 50%.
[0114] Experiment 3: Activity test of the novel QC enzyme and Aβ dual-target inhibitor of the present invention to promote the disaggregation of Aβ aggregates Test method: 1. Take 1 mg of Aβ 1-42 (Hereinafter referred to as Aβ) was added to hexafluoroisopropanol and sonicated to promote dissolution, followed by freeze-drying, redissolving in DMSO, and then diluted with cold PBS solution to obtain the Aβ monomer solution. The Aβ monomer solution was incubated at 37°C for 72 hours to obtain Aβ aggregates.
[0115] 2. Replace the Aβ monomer solution in Experiment 3 with Aβ aggregates and conduct the test according to steps 2-6 of Experiment 3.
[0116] Experimental results: The effects of dual-target inhibitors Q1-Q18 and PBD-150 on the disaggregation of Aβ aggregates are as follows: Figure 5 As shown, by Figure 5 It is known that the dual-target inhibitor Q7 exhibits the strongest deaggregation activity against Aβ aggregates, while the dual-target inhibitors Q6, Q8, Q10, and Q13 also have significant deaggregation activity against Aβ aggregates, and are significantly stronger than the positive QC enzyme inhibitor PBD-150.
[0117] The effects of different concentrations of Q7 solution on the deaggregation of Aβ aggregates are as follows: Figure 6 As shown, Figure 6 This indicates that Q7 promotes the disaggregation of Aβ aggregates in a concentration-dependent manner, and even at a 1 eq. equivalent ratio, it can produce a significant disaggregation-promoting activity of more than 40%.
[0118] Experiment 4: Cytotoxicity test of the novel QC enzyme and Aβ dual-target inhibitor of the present invention. Test method: 1. Prepare Q7 solutions with concentrations of 3.13, 6.25, 12.5, 25, 50, and 100 μM using cell culture medium.
[0119] 2. Logarithmic-phase human neuroblastoma cells SH-SY5Y were seeded into 96-well culture plates and then cultured overnight at 37°C with 5 v / v% carbon dioxide. After discarding the culture medium, Q7 solutions of different concentrations were added to the 96-well culture plates and incubated for another 24 h. After the culture was completed, the survival rate of human neuroblastoma cells SH-SY5Y under different concentrations of Q7 solution incubation conditions was determined by the CCK8 method.
[0120] 3. The dual-target inhibitors Q10, Q13, and Q15 were tested according to the methods in steps 1-2.
[0121] Experimental results: The cytotoxicity results of various dual-target inhibitors at different concentrations on human neuroblastoma cells SH-SY5Y are as follows: Figure 7 As shown, Figure 7 The results showed that at the highest tested concentration of 100 μM, the dual-target inhibitors Q10, Q13, and Q15 maintained a survival rate of nearly 90% for human neuroblastoma cells SH-SY5Y. Similarly, at a tested concentration of 50 μM, the dual-target inhibitor Q7 also maintained a survival rate of nearly 90% for SH-SY5Y cells. This indicates that the dual-target inhibitors Q7, Q10, Q13, and Q15 exhibit high safety profiles. Compared to the half-maximum QC inhibitory activity of approximately 5 μM, the therapeutic index of these dual-target inhibitors is close to or greater than 10 times, demonstrating a sufficiently safe therapeutic window.
[0122] Experiment 5: Study on the molecular docking interaction between the novel QC enzyme and the Aβ dual-target inhibitor of the present invention. Test method: The crystal structure of the QC enzyme (PDB ID: 3PBB) was obtained from the RCSB PDB protein database. The acceptor was pretreated using MOE software, including the removal of water molecules and protoligands, followed by protonation hydrogenation and energy minimization optimization. Small molecule ligands were plotted using ChemDraw software, and their geometry was optimized using Chem3D to obtain the lowest-energy, stable three-dimensional conformation. Molecular docking simulations were performed using MOE software, employing a semi-flexible docking approach. During docking, a maximum of 30 conformations were searched, and the top 5 conformations were selected and retained for subsequent results and interaction force analysis.
[0123] Experimental results: Figure 8 The results show that Q7 exhibits an extended conformation, with its skeletal structure well accommodating the active pocket. Analysis of the interactions between Q7 and the active residues reveals that the molecule forms a multi-interaction network centered on metal coordination. The terminal heterocyclic nitrogen atom of Q7 interacts with the Zn in the active center. 2+ It forms a key coordination bond, directly interfering with the catalytic function of QC enzyme. At the same time, its aromatic region forms a stable π-π stacking interaction with Phe325 and Trp329.
[0124] Furthermore, the polar groups of the molecule form hydrogen bonds with Gln304 and Trp207, and together with the surrounding hydrophobic interactions, synergistically enhance the binding stability of Q7 to the QC enzyme. In conformational superposition analysis, Q7 (green) and the protoligand PBD-150 (red) exhibit highly consistent binding trajectories. The two highly overlap in the positions of the core pharmacophore, especially the zinc-binding group, providing strong structural support for the potent inhibitory activity of Q7. Moreover, compared to the protoligand, Q7 retains the core binding mode while its benzene ring alkyne group fully occupies the hydrophobic region of the active pocket.
[0125] Experiment 6: Blood-brain barrier permeability test of the novel QC enzyme and Aβ dual-target inhibitor of the present invention. Test method: 1. Reagent preparation: 1.1 Weigh 10 mg of pig brain extract and add 500 μL of n-dodecane to dissolve it completely, so as to obtain a 2% pig brain extract solution.
[0126] 1.2 Weigh 1.36g K2HPO4 into 200mL of ultrapure water, then adjust the pH to 7.4 with KOH solution to obtain a 50mM PBS solution.
[0127] 1.3 Weigh 3.2 mg of PBD-150 and add it to 1 mL of DMSO. Dissolve it completely to obtain a 10 mM control sample solution of PBD-150. Store at -20℃.
[0128] 1.4 Weigh 3.3 mg of the dual-target inhibitor Q5 and add it to 1 mL of DMSO. Dissolve it completely to obtain a Q5 stock solution with a concentration of 10 mM. 1.5. Mix 700 μL of PBS solution with 300 μL of ethanol until homogeneous to obtain buffer A with pH 7.4. Take 20 μL of Q5 stock solution (10 mM) into a 1.5 mL EP tube, add 980 μL of buffer A, mix well, and obtain a test sample solution with a Q5 concentration of 100 μg / mL.
[0129] 1.6 Mix 680 μL of PBS solution, 300 μL of ethanol and 20 μL of DMSO thoroughly to obtain buffer B with pH 7.4.
[0130] 2. Blood-brain barrier permeability test of the dual-target inhibitor Q5: 2.1 Carefully pipette 4 μL of porcine brain extract and add it to the hydrophobic membrane of a 96-well plate, which will serve as the drug delivery pool; 2.2 Quickly pipette 200 μL of the test sample solution into a 96-well plate as the drug delivery chamber, and add 300 μL of buffer B to the receiving chamber as the receiving solution.
[0131] 2.3 Carefully place the drug delivery pool flat on the receiving pool, ensuring that the artificial lipid membrane is in full contact with the receiving liquid in the receiving pool.
[0132] 2.4. After standing at room temperature for 10 hours, carefully remove the drug delivery tank, and then use a multi-functional microplate reader to detect the OD of Q5 at its maximum absorption peak in the receiving tank. d value.
[0133] 2.5. Quickly pipette 200 μL of the test sample solution into 300 μL of buffer B, mix thoroughly, and use this as the theoretical equilibrium solution. Detect the OD of Q5 at its maximum absorption peak using a multi-functional microplate reader. t value.
[0134] 3. Prepare test sample solutions for the dual-target inhibitors Q7, Q8, Q9, Q10 and Q15 according to the methods in steps 1.4-1.5, and then perform blood-brain barrier permeability tests according to the method in step 2. 4. Perform the blood-brain barrier permeability test on the control sample solution according to the method in step 2; 5. Using buffer B as a blank control sample, the blood-brain barrier permeability was tested to obtain the background OD. b value; 6. Calculate the effective permeability Pe value using the following formula: Pe = -Vd × Va / [(Vd + Va) A × t] × ln (1-OD d , / OD t , ) Where Vd is the volume of the drug delivery tank, Va is the volume of the receiving tank, A is the permeation area, t is the permeation time, and OD is the permeation time. d , =OD d -OD b OD t , =OD t -OD b .
[0135] Experimental results: The effective penetration Pe values of dual-target inhibitors Q5, Q7, Q8, Q9, Q10, Q15 and PBD-150 are shown in Table 2 below: Table 2. Blood-brain barrier permeability results of representative dual-target inhibitors
[0136] As shown in Table 2, the Pe values of the dual-target inhibitors Q5, Q7, Q8, Q9, Q10, and Q15 were all higher than those of the positive control inhibitor PBD-150, especially the dual-target inhibitors Q5 and Q10, which showed a more significant improvement in blood-brain barrier permeability. This indicates that the dual-target inhibitors of the present invention all have improved blood-brain barrier permeability.
Claims
1. A novel dual-target inhibitor of QC enzyme and Aβ, characterized in that... The general structural formula of the inhibitor is as follows: or ; R1, R2, and R3 are each independently selected from hydrogen and methyl; R4, R5, R6, R7, and R8 are respectively hydrogen, chlorine, bromine, methyl, methoxyformyl, methoxyacetyl, ethynyl, 2-propynyloxy, phenyl, tert-butyl, and 4-chlorophenyl. Or any two adjacent groups among R4, R5, R6, R7, and R8, together with the carbon atom of the benzene ring to which they are attached, fused together to form a 4-methyl-2-oxo-2H-pyran ring; R9 is selected from bromine.
2. The novel QC enzyme and Aβ dual-target inhibitor according to claim 1, characterized in that... The inhibitor is selected from compounds with the following structural formula: 。 3. The novel QC enzyme and Aβ dual-target inhibitor according to claim 2, characterized in that... The inhibitor is selected from compounds with the following structural formula: 。 4. A method for synthesizing the novel QC enzyme and Aβ dual-target inhibitor as described in claim 1, characterized in that... Includes the following steps: S1. In the presence of an acid-binding agent, aromatic amines and bromoacetyl chloride undergo a substitution reaction to generate a bromoacetyl-aromatic amine intermediate; S2. In the presence of an acid-binding agent, the bromoacetyl-aromatic amine intermediate undergoes a substitution reaction with 1-(3-aminopropyl)imidazole or a 1-(3-aminopropyl)imidazole derivative to generate the novel QC enzyme and Aβ dual-target inhibitor.
5. The method for synthesizing the novel QC enzyme and Aβ dual-target inhibitor according to claim 4, characterized in that: The acid-binding agent is selected from at least one of potassium carbonate, sodium carbonate, cesium carbonate, triethylamine, and N,N-diisopropylethylamine.
6. The method for synthesizing the novel QC enzyme and Aβ dual-target inhibitor according to claim 4, characterized in that: In steps S1 and S2, the reaction solvent used is selected from at least one of acetone, dichloromethane, chloroform, acetonitrile, tetrahydrofuran, and dioxane.
7. The method for synthesizing the novel QC enzyme and Aβ dual-target inhibitor according to claim 4, characterized in that: In S1, the substitution reaction temperature is -5 to 15 °C, the reaction time is 0.5 to 2 h, and the molar ratio of aromatic amine, bromoacetyl chloride, and acid-binding agent is 1:1 to 4:1 to 8; in S2, the substitution reaction temperature is 30 to 80 °C, the reaction time is 1 to 4 h, and the molar ratio of bromoacetyl-aromatic amine intermediate, 1-(3-aminopropyl)imidazole or 1-(3-aminopropyl)imidazole derivative, and acid-binding agent is 1:1 to 2:1 to 10.
8. The use of the novel QC enzyme and Aβ dual-target inhibitor as described in claim 1 in the preparation of a medicament for treating diseases caused by Aβ aggregation.
9. The application of the novel QC enzyme and Aβ dual-target inhibitor according to claim 1, characterized in that: The diseases mentioned include Alzheimer's disease, vascular dementia, or glaucoma.
